Company Overview and News

 
Hexagon Resources achieves positive lithium battery test results

2018-07-17 proactiveinvestors.com.au
Hexagon Resources Ltd (ASX:HXG) has revealed impressive initial cell cycling test work results using purified, uncoated spherical graphite sourced from its McIntosh project in Western Australia.
HXG MALRY MALRF MIN

 
MinRes graphite JV begins study

2018-07-13 businessnews.com.au
Mineral Resources’ diversification strategy continues to gain ground as its joint venture with Hexagon Resources has commenced a feasibility study at the McIntosh graphite project in the Kimberley.
HXG MALRY MALRF MIN

 
MinRes-Hexagon JV starts feasibility study at McIntosh

2018-07-13 australianmining.com.au
Mineral Resources (MinRes) and Hexagon Resources have launched a feasibility study at their McIntosh graphite joint venture in the East Kimberley, Western Australia.
HXG MALRY MALRF MIN

4
Hexagon Resources shareholders give nod to graphite project joint venture with MinRes

2018-05-15 proactiveinvestors.com.au
Hexagon Resources Ltd (ASX:HXG) shareholders have approved a joint venture arrangement with Mineral Resources Limited (ASX:MIN) to develop stage I of the McIntosh Graphite Project in Western Australia.
HXG MALRY MALRF MIN

4
Mineral Resources and Hexagon Resources complete Stage 1 funding for McIntosh graphite JV

2018-03-27 australianmining.com.au
Hexagon Resources and Mineral Resources (MinRes) have today released joint statements via the ASX announcing the completion of Stage 1 funding for their ambitious McIntosh graphite joint venture.
HXG MALRY MALRF MIN

4
Hexagon Resources agreement with Mineral Resources will result in development of graphite project

2018-03-27 proactiveinvestors.com.au
Hexagon Resources Ltd (ASX:HXG) has signed an agreement with Mineral Resources Limited (ASX:MIN) leading to development of stage I of the McIntosh Graphite Project in Western Australia.
HXG MALRY MALRF MIN

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:HXG / HEXAGON RESOURCES LIMITED on message board site Silicon Investor.

Hixon Gold Resources Hixon Gold Resources Hixon Gold Resources